Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
about
DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data.A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study.Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix.Measurement of blood-brain barrier permeability with t1-weighted dynamic contrast-enhanced MRI in brain tumors: a comparative study with two different algorithms.Influence of B1-Inhomogeneity on Pharmacokinetic Modeling of Dynamic Contrast-Enhanced MRI: A Simulation StudyEstimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.Muscle-based pharmacokinetic modeling of marrow perfusion for osteoporotic bone in females.Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.Reconstruction of dynamic contrast enhanced magnetic resonance imaging of the breast with temporal constraintsTemporal/spatial resolution improvement of in vivo DCE-MRI with compressed sensing-optimized FLASHReview of treatment assessment using DCE-MRI in breast cancer radiation therapy.Mapping Tumor Hypoxia In Vivo Using Pattern Recognition of Dynamic Contrast-enhanced MRI Data.Gaussian mixture model-based classification of dynamic contrast enhanced MRI data for identifying diverse tumor microenvironments: preliminary resultsDynamic contrast-enhanced MRI in clinical oncology: current status and future directions.Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.Simulation study of the effect of golden-angle KWIC with generalized kinetic model analysis on diagnostic accuracy for lesion discrimination.Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastasesVisualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment.The parametric response map is an imaging biomarker for early cancer treatment outcome.MRI for assessing antivascular cancer treatments.The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.Model-Free Visualization of Suspicious Lesions in Breast MRI Based on Supervised and Unsupervised LearningDynamic contrast-enhanced MRI for monitoring antiangiogenic treatment: determination of accurate and reliable perfusion parameters in a longitudinal study of a mouse xenograft model.Perfusion measurement using DCE-MRI: implications for hyperthermia.Role of quantitative pharmacokinetic parameter (transfer constant: K(trans)) in the characterization of breast lesions on MRI.Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.Supine breast US: how to correlate breast lesions from prone MRI.Assessment of bone perfusion with contrast-enhanced magnetic resonance imaging.Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors.Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.Imaging in prostate cancer diagnosis: present role and future perspectives.Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma".Models and methods for analyzing DCE-MRI: a review.Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance.Single-scan rest/stress imaging with 99mTc-Sestamibi and cadmium zinc telluride-based SPECT for hyperemic flow quantification: A feasibility study evaluated with cardiac magnetic resonance imaging.Dynamic contrast-enhanced MRI for oncology drug development.Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness.Induction of luciferase activity under the control of an hsp70 promoter using high-intensity focused ultrasound: combination of bioluminescence and MRI imaging in three different tumour models.Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
P2860
Q30687678-1ED3BDF2-1466-4404-97C5-1C52C2CA6B7CQ33614436-73F94182-65E7-4729-B4CD-DA8193F785FEQ33620142-0EEC0691-5733-46D3-A85D-8F82D59298A4Q33711249-5C8B10FE-F2D2-48D2-9C05-98C8F0CE80D1Q33736299-652A8688-A566-4AB2-89A8-2F8165656F8EQ33744660-833BA90B-45E1-4E5A-97B1-57ACB3D11897Q33805017-17399A17-5436-4282-9DCC-4F49556BCB90Q33925417-98C87DED-A625-4BC7-B1F1-BF7F43559B31Q33978742-CFDF2A0B-F146-4D35-ADB2-77F793F31358Q34215586-C232D225-8438-4C40-9DC1-41CD81AAC5D0Q34367593-E6068489-6655-419C-9275-077DD2B736BDQ34552360-13C1FE20-D9B3-4544-ADCF-74E73D4925B6Q34601310-8DA1C676-C888-4566-9943-46EECF2229BEQ34918635-32E28E83-0DC6-4601-8E6F-01EBE458AF69Q35078389-1C80A7C8-C506-4C78-8114-41777380C313Q35215149-D4517AA7-FEF3-423E-8758-9E6252532912Q35223964-11C2E0C3-4B37-4647-B253-4C124E431877Q35790990-6A0D4BA9-800C-49D9-A45E-2F04AD453B2DQ35838767-92ABF335-CB37-4A92-8BDA-C1387D124BFEQ35905005-6BBA4330-C3D6-42C6-987B-E60A03145FB1Q36616812-6F906A37-6739-48CE-84FF-A6400385B224Q37004342-44D92E84-D167-4D8A-9B3F-4CC149E8DA36Q37050403-0CA6D97A-7295-449C-A411-9028F27183E6Q37063506-74044F97-7B2D-4555-8F18-26E9E24C4BF4Q37080581-3D0B94E8-3F4A-48EB-B58E-EBEE96CDA3A9Q37109541-F1F3F179-CDEB-467C-8540-DD9B489517E3Q37178842-8F438373-EF2B-4C2D-A27F-4A548DD98EDEQ37439974-9FF01994-CC24-4763-910E-81D4005F1E39Q37510716-95A1222C-B4DA-4A66-B813-02BB1E4F69F7Q37823843-D6CA7020-8095-4765-B99F-C7E398F409D9Q37849513-0CEF165E-2F19-4371-AAC6-293465129D73Q38071645-528590D3-C01F-41CE-86DA-870514E5F4D6Q38282639-BE0A9A85-AD99-43D9-906D-63B5ABA567E0Q38392814-B04F788C-298A-45A3-B515-BE535A3A1C9AQ38619851-52B7508B-9DAE-4673-BB35-31823B9868F3Q38725827-6062A79D-F736-4100-9B96-6E6394D16C3FQ38727633-0A54F68C-6E79-47FD-9B97-4699445E9E5DQ39580218-4B8921CD-0C5A-4456-87A8-60424748FA13Q41484298-578B394A-CBCF-43C7-A046-60487406DB6AQ41559635-6B511BCA-2F3C-44A6-BD26-21269DA5D7EA
P2860
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
@en
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
@nl
type
label
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
@en
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
@nl
prefLabel
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
@en
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography.
@en
P2093
P2860
P304
P356
10.1002/MRM.1910330408
P577
1995-04-01T00:00:00Z